Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S. Saridaki Z, et al. Among authors: tejpar s. Clin Cancer Res. 2014 Sep 1;20(17):4499-4510. doi: 10.1158/1078-0432.CCR-14-0348. Clin Cancer Res. 2014. PMID: 25183481 Free PMC article.
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S. De Roock W, et al. Among authors: tejpar s. Ann Oncol. 2008 Mar;19(3):508-15. doi: 10.1093/annonc/mdm496. Epub 2007 Nov 12. Ann Oncol. 2008. PMID: 17998284 Free article.
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.
Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, Biesmans B, De Roock W, Capoen A, Debiec-Rychter M, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S. Personeni N, et al. Among authors: tejpar s. Clin Cancer Res. 2008 Sep 15;14(18):5869-76. doi: 10.1158/1078-0432.CCR-08-0449. Clin Cancer Res. 2008. PMID: 18794099
K-ras mutations and cetuximab in colorectal cancer.
De Roock W, Lambrechts D, Tejpar S. De Roock W, et al. Among authors: tejpar s. N Engl J Med. 2009 Feb 19;360(8):834; author reply 835-6. N Engl J Med. 2009. PMID: 19238676 No abstract available.
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Van Cutsem E, et al. Among authors: tejpar s. N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019. N Engl J Med. 2009. PMID: 19339720 Free article. Clinical Trial.
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, Humblet Y, Pénault-Llorca F, De Hertogh G, Laurent-Puig P, Van Cutsem E, Tejpar S. Jacobs B, et al. Among authors: tejpar s. J Clin Oncol. 2009 Oct 20;27(30):5068-74. doi: 10.1200/JCO.2008.21.3744. Epub 2009 Sep 8. J Clin Oncol. 2009. PMID: 19738126
243 results